Evolus, Inc. (LON:0K16)
14.58
+0.43 (3.00%)
At close: Jan 31, 2025
Evolus Company Description
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.
Country | United States |
Founded | 2012 |
Industry | Medical - Pharmaceuticals |
Sector | Healthcare |
Employees | 332 |
CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive Newport Beach, Delaware 92660 United States | |
Phone | 949 284 4555 |
Website | evolus.com |
Stock Details
Ticker Symbol | 0K16 |
Exchange | London Stock Exchange |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
ISIN Number | US30052C1071 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David Moatazedi | Chief Executive Officer |
Sandra Beaver | Chief Financial Officer |
Nareg Sagherian | Head of Investor Relations |